Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term therapy with deferiprone

N F Olivieri1

  • 1The Hospital for Sick Children, Toronto, Canada.

Acta Haematologica
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Deferiprone effectively treats iron overload in thalassemia major by lowering body iron. However, the risk of agranulocytosis requires careful patient selection and ongoing study for FDA approval.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases.

Clinical drug investigation·2016
Same author

Pharmacokinetics of arginine butyrate in patients with hemoglobinopathy.

Environmental toxicology and pharmacology·2011
Same author

Haemoglobin E beta thalassaemia in Sri Lanka.

Lancet (London, England)·2005
Same author

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

Lancet (London, England)·2003
Same author

Identification of two new alpha-thalassemia mutations in exon 2 of the alpha1-globin gene.

Hemoglobin·2002
Same author

Secondary iron overload.

Hematology. American Society of Hematology. Education Program·2001

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Iron overload is a serious complication in thalassemia major patients.
  • Deferiprone has demonstrated efficacy in reducing body iron levels.
  • Deferoxamine is a current treatment, but patient adherence can be an issue.

Purpose of the Study:

  • To evaluate the efficacy and safety of deferiprone for iron overload in thalassemia major.
  • To assess the risk of agranulocytosis associated with deferiprone treatment.
  • To gather data for potential FDA licensing of deferiprone.

Main Methods:

  • Analysis of data from several clinical trials.
  • Prospective multicenter trial in Canada, Italy, and the United States.
  • Monitoring for adverse events, specifically agranulocytosis.

Related Experiment Videos

Main Results:

  • Deferiprone induces sustained decreases in body iron.
  • Achieved iron concentrations are associated with reduced iron overload complications.
  • The incidence of agranulocytosis is under active investigation.

Conclusions:

  • Deferiprone is an effective treatment for iron overload in thalassemia major.
  • Careful patient evaluation is necessary due to the risk of agranulocytosis.
  • Further data from ongoing trials are crucial for regulatory decisions.